Gossamer Bio, Inc.
General ticker "GOSS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $356.2M (TTM average)
Gossamer Bio, Inc. follows the US Stock Market performance with the rate: 30.8%.
Estimated limits based on current volatility of 4.2%: low 0.43$, high 0.47$
Factors to consider:
- Total employees count: 145 (+7.4%) as of 2024
- Top business risk factors: Clinical trial delays, Regulatory and compliance, Dependency on third parties, Geopolitical risks, Market competition
- Current price 77.3% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.96$, 5.59$]
- 2026-12-31 to 2027-12-31 estimated range: [1.52$, 4.38$]
Financial Metrics affecting the GOSS estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.31 <= 0.07
- Negative: Shareholder equity ratio, % of -71.27 <= 19.49
- Negative: negative Net income
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Positive: Investing cash flow per share per price, % of 20.36 > -0.65
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term GOSS quotes
Long-term GOSS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $114.70MM | $48.47MM |
| Operating Expenses | $183.76MM | $174.62MM | $211.72MM |
| Operating Income | $-183.76MM | $-59.92MM | $-163.25MM |
| Non-Operating Income | $3.94MM | $4.28MM | $-7.21MM |
| Interest Expense | $13.51MM | $11.52MM | $10.99MM |
| R&D Expense | $145.30MM | $138.49MM | $174.09MM |
| Income(Loss) | $-179.82MM | $-55.63MM | $-170.46MM |
| Taxes | $0.00MM | $0.89MM | $-0.09MM |
| Profit(Loss)* | $-179.82MM | $-56.53MM | $-170.37MM |
| Stockholders Equity | $62.77MM | $29.49MM | $-122.76MM |
| Assets | $311.92MM | $315.29MM | $172.25MM |
| Operating Cash Flow | $-159.16MM | $-3.47MM | $-171.27MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.08MM |
| Investing Cash Flow | $-110.97MM | $29.02MM | $156.36MM |
| Financing Cash Flow | $190.15MM | $-11.49MM | $6.42MM |
| Earnings Per Share** | $-0.80 | $-0.25 | $-0.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.